EP3589646A4 - CD19 COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY - Google Patents

CD19 COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY Download PDF

Info

Publication number
EP3589646A4
EP3589646A4 EP18760420.2A EP18760420A EP3589646A4 EP 3589646 A4 EP3589646 A4 EP 3589646A4 EP 18760420 A EP18760420 A EP 18760420A EP 3589646 A4 EP3589646 A4 EP 3589646A4
Authority
EP
European Patent Office
Prior art keywords
immunotherapy
compositions
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP18760420.2A
Other languages
German (de)
French (fr)
Other versions
EP3589646A1 (en
Inventor
Vipin Suri
Michael Joseph BRISKIN
Brian DOLINSKI
Kutlu Goksu ELPEK
Dan Jun LI
Scott Francis HELLER
Michelle Lynn OLS
Dexue Sun
Nicole KOSMIDER
Abhishek KULKARNI
Vijaya BALAKRISHNAN
Tucker EZELL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Obsidian Therapeutics Inc
Original Assignee
Obsidian Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Obsidian Therapeutics Inc filed Critical Obsidian Therapeutics Inc
Publication of EP3589646A1 publication Critical patent/EP3589646A1/en
Publication of EP3589646A4 publication Critical patent/EP3589646A4/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0026—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on CH-NH groups of donors (1.5)
    • C12N9/0028—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on CH-NH groups of donors (1.5) with NAD or NADP as acceptor (1.5.1)
    • C12N9/003—Dihydrofolate reductase [DHFR] (1.5.1.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/804—Blood cells [leukemia, lymphoma]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/49—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Mycology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
EP18760420.2A 2017-03-03 2018-03-02 CD19 COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY Pending EP3589646A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762466601P 2017-03-03 2017-03-03
US201762484052P 2017-04-11 2017-04-11
PCT/US2018/020741 WO2018161017A1 (en) 2017-03-03 2018-03-02 Cd19 compositions and methods for immunotherapy

Publications (2)

Publication Number Publication Date
EP3589646A1 EP3589646A1 (en) 2020-01-08
EP3589646A4 true EP3589646A4 (en) 2021-01-20

Family

ID=63371272

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18760420.2A Pending EP3589646A4 (en) 2017-03-03 2018-03-02 CD19 COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY

Country Status (7)

Country Link
EP (1) EP3589646A4 (en)
JP (3) JP7341900B2 (en)
KR (1) KR102746901B1 (en)
CN (1) CN110831961B (en)
AU (2) AU2018227583B2 (en)
SG (2) SG10202001869VA (en)
WO (1) WO2018161017A1 (en)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
CN105939767B (en) 2014-01-08 2018-04-06 弗洛设计声能学公司 Sound electrophoretic apparatus with alliteration electrophoresis chamber
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
US11241485B2 (en) 2017-06-12 2022-02-08 Obsidian Therapeutics, Inc. PDE5 compositions and methods for immunotherapy
CN114900773A (en) 2017-12-14 2022-08-12 弗洛设计声能学公司 Acoustophoretic system, method for operating acoustophoretic system, and method for controlling acoustic transducer and acoustic system
WO2019118918A1 (en) * 2017-12-15 2019-06-20 Aleta Biotherapeutics Inc. Cd19 variants
KR102907902B1 (en) * 2018-08-01 2026-01-02 난트퀘스트, 인크. A quadricistronic system comprising a homing receptor or a cytokine, and chimeric antigen receptor for genetic modification of immunotherapies
US12421524B2 (en) 2018-09-24 2025-09-23 Merck Sharp & Dohme Llc Expression vectors for eukaryotic expression systems
CN113853437A (en) * 2018-11-07 2021-12-28 阿库斯股份有限公司 Use of Adeno-Associated Virus Vectors for Correction of Gene Defects/Expression of Proteins in Hair Cells and Sertoli cells in the Inner Ear
CN113226340A (en) 2018-11-26 2021-08-06 恩卡尔塔公司 Methods of simultaneously expanding multiple immune cell types, related compositions, and uses thereof in cancer immunotherapy
WO2020123716A1 (en) * 2018-12-11 2020-06-18 Obsidian Therapeutics, Inc. Membrane bound il12 compositions and methods for tunable regulation
KR20250116790A (en) 2018-12-12 2025-08-01 카이트 파마 인코포레이티드 Chimeric antigen receptors and car-t cells and methods of use
CN109735558B (en) * 2018-12-12 2022-04-15 中南大学 Recombinant CAR19-IL24 gene, lentiviral vector, CAR19-IL24-T cell and application
WO2020156335A1 (en) * 2019-01-29 2020-08-06 上海交通大学 Chimeric antigen receptor and use thereof
AU2020218446B2 (en) * 2019-02-04 2023-05-25 National University Corporation Ehime University "CAR LIBRARY AND scFv MANUFACTURING METHOD
KR20210132668A (en) * 2019-02-21 2021-11-04 아르벨 리미티드 Artificial Immunosurveillance Chimeric Antigen Receptor (AI-CAR) and Cells Expressing It
CN113811549A (en) 2019-02-21 2021-12-17 Xencor股份有限公司 Untargeted and targeted IL-10 FC fusion proteins
US12590135B2 (en) 2019-03-01 2026-03-31 Universität Für Bodenkultur Wien Stabilized extracellular domain of CD19
KR20210137085A (en) * 2019-03-05 2021-11-17 엔카르타, 인크. CD19 induced chimeric antigen receptor and use thereof in immunotherapy
BR112021017744A2 (en) * 2019-03-08 2021-11-16 Obsidian Therapeutics Inc CD40L Compositions and Methods for Adjustable Regulation
BR112021017770A2 (en) * 2019-03-08 2021-11-16 Obsidian Therapeutics Inc CD40L Compositions and Methods for Adjustable Regulation
CN113710697A (en) * 2019-03-15 2021-11-26 美国政府(由卫生和人类服务部的部长所代表) Chimeric adaptors and kinase signaling proteins and their use in immunotherapy
BR112021021178A2 (en) * 2019-04-26 2022-03-15 Allogene Therapeutics Inc Rituximab-resistant chimeric antigen receptors and uses thereof
CN110079504A (en) * 2019-05-06 2019-08-02 山东大学第二医院 A kind of CAR-T cell containing unstable structure domain and preparation method thereof and adjust CAR-T cell function method
CN110075275B (en) * 2019-05-15 2023-03-24 苏州大学 Application of IL-36 beta
US20220162644A1 (en) * 2019-05-29 2022-05-26 Orbis Health Solutions, Llc Delivery vectors and particles for expressing chimeric receptors and methods of using the same
WO2020252404A1 (en) 2019-06-12 2020-12-17 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
CA3140668A1 (en) * 2019-06-12 2020-12-17 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
AU2020291946B2 (en) * 2019-06-14 2026-08-06 Dana-Farber Cancer Institute, Inc. Antibodies against PD-1 and methods of use thereof
CN110818803B (en) * 2019-07-24 2023-01-03 浙江启新生物技术有限公司 Chimeric antigen receptor-T cell for secreting and expressing IL15RA-IL15 fusion protein and CCL21 chemokine and application
AU2020331963A1 (en) * 2019-08-19 2022-03-03 Elpis Biopharmaceuticals Anti-CD19 antibodies and uses thereof
US20210128617A1 (en) * 2019-08-27 2021-05-06 The Trustees Of The University Of Pennsylvania SYNTHETIC CARS TO TREAT IL13R-alpha-2 POSITIVE HUMAN AND CANINE TUMORS
US20230092895A1 (en) 2019-08-30 2023-03-23 Obsidian Therapeutics, Inc. Tandem cd19 car-based compositions and methods for immunotherapy
WO2021046451A1 (en) * 2019-09-06 2021-03-11 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
CN114651003A (en) 2019-09-10 2022-06-21 黑曜石疗法公司 CA2-IL15 fusion protein for adjustable regulation
CN112500492B (en) * 2019-09-13 2023-08-04 中国科学院分子细胞科学卓越创新中心 Chimeric antigen receptor and application thereof
AU2020361683A1 (en) * 2019-10-11 2022-05-19 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting CD13 and TIM-3 with CAR T cells to treat acute myeloid leukemia
EP4065696A4 (en) * 2019-11-27 2024-02-07 Board of Regents, The University of Texas System COMBINED CAR TRANSDUCTION AND CRISPR GENE EDITING OF T CELLS ON A LARGE SCALE
WO2021108543A1 (en) * 2019-11-27 2021-06-03 The Trustees Of The University Of Pennsylvania Anti-cd3 scfv and cytokine producing artificial antigen presenting cells
AU2021205416B2 (en) * 2020-01-08 2026-08-06 Obsidian Therapeutics, Inc. Compositions and methods for tunable regulation of transcription
US11230699B2 (en) 2020-01-28 2022-01-25 Immunitybio, Inc. Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors
JP7439280B2 (en) * 2020-02-13 2024-02-27 イミュノファーム テクノロジー カンパニー リミテッド Optimization of chimeric antigen receptors
CN115427451B (en) * 2020-02-14 2026-02-17 北京永泰瑞科生物科技有限公司 Immune cells overexpressing externally introduced cell signaling regulators and their applications
US11896619B2 (en) * 2020-03-10 2024-02-13 Massachusetts Institute Of Technology Compositions and methods for immunotherapy of NPM1c-positive cancer
IL296242A (en) * 2020-03-10 2022-11-01 Massachusetts Inst Technology Methods for producing engineered memory-like nk cells and preparations containing them
CN113214396B (en) * 2020-07-31 2022-04-19 北京市神经外科研究所 Single-chain antibody of anti-TIM 3 and application thereof in preparing medicine for treating tumor
CN114057874B (en) * 2020-07-31 2023-05-05 北京市神经外科研究所 anti-CD 44 single-chain antibody and application thereof in preparation of medicines for treating tumors
IL300903A (en) * 2020-09-02 2023-04-01 Nkarta Inc Enhanced expansion and cytotoxicity of engineered natural killer cells and uses thereof
EP4208176A4 (en) * 2020-09-04 2025-06-25 Gavish-Galilee Bio Applications Ltd. INHIBITORY CHIMERIC ANTIGEN RECEPTOR (ICAR)/ACTIVATING ANTIGEN RECEPTOR (ACAR) CONSTRUCTS FOR USE IN CANCER THERAPIES
US20230220025A1 (en) * 2020-09-04 2023-07-13 Heartseed Inc. Quality Improving Agent for IPS Cells, Method of Producing IPS Cells, IPS Cells, and Composition for Producing IPS Cells
WO2022109443A1 (en) * 2020-11-23 2022-05-27 The Regents Of The University Of Michigan Single-chain antibody against flavivirus ns1 protein
CN112830974B (en) * 2021-01-08 2022-07-26 深圳市珈钰生物科技有限公司 Chimeric antigen receptor, carrier, human dendritic cell, cell line, solid tumor treatment drug, preparation method and application
US20240115607A1 (en) * 2021-01-26 2024-04-11 Cytocares (Shanghai) Inc. Chimeric antigen receptor (car) constructs and nk cells expressing car constructs
CN112795543B (en) * 2021-02-04 2022-09-27 华中农业大学 Hybridoma cell strain, monoclonal antibody secreted by hybridoma cell strain and resisting grass carp IL-15R alpha and application of monoclonal antibody
GB202102049D0 (en) * 2021-02-13 2021-03-31 Psioxus Therapeutics Ltd Viruses
CN113736810B (en) * 2021-09-08 2024-05-24 苏州因特药物研发有限公司 Construct, vector, protein, cell, preparation method, product and application
CN114129718B (en) * 2021-10-19 2024-05-03 华东师范大学 Nanometer delivery system for in-vivo self-assembly CAR-T, and preparation method and application thereof
CN114558126B (en) * 2021-11-04 2024-11-08 苏州大学附属第一医院 Combined application of sequential infusion of CD19 CAR-T and BCMA CAR-T cells in patients with acute leukemia with immune-mediated platelet transfusion failure
US20250332197A1 (en) * 2022-03-18 2025-10-30 Sunshine Lake Pharma Co., Ltd. Claudin18.2 humanized antibody and application thereof
CA3260584A1 (en) 2022-07-05 2024-01-11 Neomics Pharmaceuticals Llc Chimeric antigen receptor comprising bcma nanobody linked to a chimeric intracellular signaling domain
WO2024189583A1 (en) * 2023-03-15 2024-09-19 Kyoto Prefectural Public University Corporation Peptide expression constructs and uses thereof
CN116516007B (en) * 2023-04-18 2024-01-19 华中科技大学同济医学院附属协和医院 Method for detecting CD19 expression
WO2025160432A1 (en) * 2024-01-26 2025-07-31 Poseida Therapeutics, Inc. Methods and compositions for enhancing in vivo persistence and potency of cell therapy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8173792B2 (en) * 2007-02-09 2012-05-08 The Board Of Trustees Of The Leland Stanford Junior University Method for regulating protein function in cells using synthetic small molecules
US20140010791A1 (en) * 2008-05-07 2014-01-09 The Board Of Trustees Of The Leland Stanford Junior University Methods for regulating protein function in cells in vivo using synthetic small molecules
WO2018231759A1 (en) * 2017-06-12 2018-12-20 Obsidian Therapeutics, Inc. Pde5 compositions and methods for immunotherapy

Family Cites Families (161)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6531A (en) 1849-06-19 Beed musical instrument
US7094A (en) 1850-02-12 Connecting trucks with car-bodies
US568A (en) 1838-01-09 Sphebometeb for
US451A (en) 1837-11-04 Island
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US4851341A (en) 1986-12-19 1989-07-25 Immunex Corporation Immunoaffinity purification system
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US4965197A (en) 1987-06-12 1990-10-23 Massachusetts Institute Of Technology Coryneform expression and secretion system
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
CA2032914A1 (en) 1989-12-26 1991-06-27 Peter C.K. Lau Use of bacterial lipoprotein amino terminus in fusion plasmids for in vivo expression of lipid modified polypeptides
US5525491A (en) 1991-02-27 1996-06-11 Creative Biomolecules, Inc. Serine-rich peptide linkers
DE69233528T2 (en) 1991-11-25 2006-03-16 Enzon, Inc. Process for the preparation of multivalent antigen-binding proteins
WO1993018181A1 (en) 1992-03-13 1993-09-16 Cornell Research Foundation, Inc. Synthetic gene sequence for a signal peptide
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
DE69334275D1 (en) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobulins without a light chain
WO1994012520A1 (en) 1992-11-20 1994-06-09 Enzon, Inc. Linker for linked fusion polypeptides
WO1994025591A1 (en) 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US6805861B2 (en) 1996-01-17 2004-10-19 Imperial College Innovations Limited Immunotherapy using cytotoxic T lymphocytes (CTL)
AU4645697A (en) 1996-09-11 1998-04-02 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Aav4 vector and uses thereof
EP0930892A1 (en) 1996-10-16 1999-07-28 The Johns Hopkins University Cytokine enhanced immunotherapy for brain tumors
US6348584B1 (en) 1996-10-17 2002-02-19 John Edward Hodgson Fibronectin binding protein compounds
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
JP3614866B2 (en) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ，インコーポレイティド Artificial antibody polypeptide
EP1021549A2 (en) 1997-09-19 2000-07-26 Sequitur, Inc. SENSE mRNA THERAPY
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
KR100316347B1 (en) 1998-09-15 2002-08-27 한미약품(주) Recombinant microorganisms expressing a fusion protein of Escherichia coli enterotoxin II signal peptide and fusion protein of human growth hormone and a method of producing human growth hormone using the same
WO2002005146A2 (en) 2000-07-10 2002-01-17 Xencor, Inc. Method for disigning protein libraries with altered immunogenicity
US7575924B2 (en) 2000-11-13 2009-08-18 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
DE10057397A1 (en) 2000-11-18 2002-05-23 Hella Kg Hueck & Co Device for oil level measurement in internal combustion engine, particularly in road vehicle, has housing at base of which vertically extending, elongated damping container is fitted, which is connectable to oil feed
EP1436316B1 (en) 2001-04-30 2008-01-23 ZyStor Therapeutics , Inc. Subcellular targeting of therapeutic proteins
WO2002092134A1 (en) 2001-05-14 2002-11-21 Cell Genesys, Inc. Lentiviral vectors encoding clotting factors for gene therapy
ATE291925T1 (en) 2001-06-05 2005-04-15 Curevac Gmbh STABILIZED MRNA WITH INCREASED G/C CONTENT AND OPTIMIZED CODON USAGE FOR GENE THERAPY
ATE527347T1 (en) 2001-08-02 2011-10-15 Inst Clayton De La Rech METHODS AND COMPOSITIONS RELATED TO IMPROVED LENTIVIRUS VECTOR PRODUCTION SYSTEMS
CA2462628C (en) 2001-10-02 2019-08-20 Institut Clayton De La Recherche Restricted expression lentiviral vectors
CN103589692B (en) 2001-11-13 2018-07-24 宾夕法尼亚大学托管会 The method for the novel sequences that detection and/or identification adeno-associated virus (AAV) sequence and separation are identified
EP1463805B1 (en) 2001-12-17 2014-10-22 The Trustees of The University of Pennsylvania Adeno-associated virus (aav) serotype 9 sequences, vectors containing same, and uses therefor
DE10162480A1 (en) 2001-12-19 2003-08-07 Ingmar Hoerr The application of mRNA for use as a therapeutic agent against tumor diseases
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
GB0202018D0 (en) 2002-01-29 2002-03-13 Sense Proteomic Ltd Tag and method
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
GB0217033D0 (en) 2002-07-23 2002-08-28 Delta Biotechnology Ltd Gene and polypeptide sequences
GB0220467D0 (en) 2002-09-03 2002-10-09 Oxford Biomedica Ltd Composition
ES2348868T3 (en) 2002-12-13 2010-12-16 Genetix Pharmaceuticals Inc. THERAPEUTIC RETROVIRAL VECTORS FOR GENE THERAPY.
AU2004204942A1 (en) 2003-01-08 2004-07-29 Xencor, Inc Novel proteins with altered immunogenicity
ATE532793T1 (en) 2003-07-03 2011-11-15 Avatar Biotechnologies Inc METHOD FOR PRODUCING MOLECULES WITH REDUCED IMMUNOGENICITY
GB0316089D0 (en) 2003-07-09 2003-08-13 Xo Bioscience Ltd Differentiation method
JP4733635B2 (en) * 2003-07-31 2011-07-27 イミューノメディクス、インコーポレイテッド Anti-CD19 antibody
US20070141666A1 (en) 2003-09-26 2007-06-21 Applied Research Systems Ars Holding N.V. Leader sequences for use in production of proteins
EP1668143B1 (en) 2003-09-30 2013-03-20 The Trustees of The University of Pennsylvania Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor
US20130266551A1 (en) * 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
WO2006042333A2 (en) 2004-10-12 2006-04-20 Xencor, Inc. Prediction and assessment of immunogenicity
DE23193606T1 (en) 2005-04-07 2024-02-15 The Trustees Of The University Of Pennsylvania METHOD FOR INCREASE THE FUNCTION OF AN AAV VECTOR
DE102005023170A1 (en) 2005-05-19 2006-11-23 Curevac Gmbh Optimized formulation for mRNA
US9012219B2 (en) 2005-08-23 2015-04-21 The Trustees Of The University Of Pennsylvania RNA preparations comprising purified modified RNA for reprogramming cells
PL2578685T3 (en) 2005-08-23 2020-01-31 The Trustees Of The University Of Pennsylvania Rna containing modified nucleosides and methods of use thereof
EP1757703A3 (en) 2005-08-24 2007-12-05 Medizinische Hochschule Hannover Self-inactivating retroviral vector
JP2007054069A (en) 2005-08-24 2007-03-08 Medizinische Hochschule Hannover Self-inactivating retroviral vector
EP1757702A1 (en) 2005-08-24 2007-02-28 Medizinische Hochschule Hannover Self-inactivating gammaretroviral vector
US8980246B2 (en) 2005-09-07 2015-03-17 Sillajen Biotherapeutics, Inc. Oncolytic vaccinia virus cancer therapy
DE102005046490A1 (en) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz New nucleic acid molecule comprising promoter, a transcriptable nucleic acid sequence, a first and second nucleic acid sequence for producing modified RNA with transcriptional stability and translational efficiency
EP1777294A1 (en) 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
US8603457B2 (en) 2005-12-02 2013-12-10 University Of Rochester Nonsense suppression and genetic codon alteration by targeted modification
US8706219B2 (en) 2005-12-22 2014-04-22 Board Of Regents, The University Of Texas System Method and apparatus for monitoring an organ of a patient
KR100787393B1 (en) * 2006-03-23 2007-12-21 학교법인 한림대학교 506 Cell-transducing fusion protein which comprising FK506 binding protein and protein transducing domain
DE102006044841A1 (en) 2006-09-22 2008-04-03 Wacker Chemie Ag Signal peptide for the production of recombinant proteins
DE102006051516A1 (en) 2006-10-31 2008-05-08 Curevac Gmbh (Base) modified RNA to increase the expression of a protein
US20090181458A1 (en) 2006-12-04 2009-07-16 Thomas David Reed Tubulo-vesicular structure localization signals
WO2008140615A2 (en) 2006-12-21 2008-11-20 Novozymes, Inc. Modified messenger rna stabilizing sequences for expressing genes in bacterial cells
DE102007001370A1 (en) 2007-01-09 2008-07-10 Curevac Gmbh RNA-encoded antibodies
EP2132322A4 (en) 2007-03-02 2013-02-20 Richmond Chemical Corp Method to increase the yield and improve purification of products from transaminase reactions
DK2147104T3 (en) 2007-05-21 2015-12-14 Danisco Us Inc USING A ASPARAGINPROTEASE- (NSP24) SIGNAL SEQUENCE FOR heterologous protein EXPRESSION
EP2173378B1 (en) 2007-06-27 2014-03-19 Admune Therapeutics LLC Complexes of il-15 and il-15ralpha and uses thereof
US8039214B2 (en) 2007-06-29 2011-10-18 Cellscript, Inc. Synthesis of tagged nucleic acids
ES2708856T3 (en) 2007-08-03 2019-04-11 Pasteur Institut Vectors of lentiviral gene transfer and its medicinal applications
US9809797B2 (en) 2007-10-03 2017-11-07 National Institutes Of Health (Nih) U.S. Dept. Of Health And Human Services (Dhhs) Division Of Extramural Inventions And Technology Enhanced generation of cytotoxic T-lymphocytes by IL-21 mediated FOXP3 suppression
EP2072618A1 (en) 2007-12-14 2009-06-24 Johannes Gutenberg-Universität Mainz Use of RNA for reprogramming somatic cells
WO2009127230A1 (en) 2008-04-16 2009-10-22 Curevac Gmbh MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION
WO2010014922A2 (en) 2008-08-01 2010-02-04 The Regents Of The University Of Michigan Protein purification tags and uses thereof
WO2010042490A1 (en) 2008-10-06 2010-04-15 Boston Medical Center Corporation A single lentiviral vector system for induced pluripotent (ips) stem cells derivation
EP2401365B1 (en) 2009-02-24 2016-04-27 The Scripps Research Institute Reengineering mrna primary structure for enhanced protein production
MX355507B (en) 2009-03-09 2018-04-19 Bioatla Llc Mirac proteins.
EP2414524B1 (en) 2009-04-03 2017-08-23 Centre National De La Recherche Scientifique Gene transfer vectors comprising genetic insulator elements and methods to identify genetic insulator elements
US20120164118A1 (en) 2009-05-04 2012-06-28 Fred Hutchinson Cancer Research Center Cocal vesiculovirus envelope pseudotyped retroviral vectors
AU2010250452B2 (en) 2009-05-20 2014-06-05 Toray Industries, Inc. Cell membrane-permeable peptides
US8399625B1 (en) 2009-06-25 2013-03-19 ESBATech, an Alcon Biomedical Research Unit, LLC Acceptor framework for CDR grafting
EP2451475A2 (en) 2009-07-06 2012-05-16 Novartis AG Self replicating rna molecules and uses thereof
EA022786B1 (en) 2009-07-31 2016-03-31 Этрис Гмбх Rna with a combination of unmodified and modified nucleotides for protein expression
KR101410845B1 (en) 2009-09-10 2014-06-23 바이오콘 리미티드 Novel prolipase-bovine trypsinogen fusion proteins
EP2478002B1 (en) 2009-09-18 2015-02-25 University Of Houston Small peptide modulators of potassium channel trafficking
US20130012687A1 (en) 2009-09-21 2013-01-10 The Board Of Trustees Of The Leland Stanford Junior University Inducible self-cleaving protease tag and method of purifying recombinant proteins using the same
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
EP2501414B1 (en) 2009-11-17 2018-01-10 The Trustees Of The University Of Pennsylvania Smndelta7 degron: novel compositions and methods of use
SI2506857T1 (en) 2009-12-01 2018-08-31 Translate Bio, Inc. Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases
ES2769129T3 (en) 2009-12-07 2020-06-24 Univ Pennsylvania RNA preparations comprising purified modified RNA to reprogram cells
WO2011109726A2 (en) 2010-03-05 2011-09-09 Bioatla Llc Homologous multi-specific antibodies
WO2011130624A2 (en) 2010-04-16 2011-10-20 Immune Disease Institute, Inc. Sustained polypeptide expression from synthetic, modified rnas and uses thereof
US9314516B2 (en) 2010-05-04 2016-04-19 Cassian Yee Conditional superagonist CTL ligands for the promotion of tumor-specific CTL responses
GB201008682D0 (en) 2010-05-25 2010-07-07 Vib Vzw Epitope tag for affinity based applications
JP6251570B2 (en) 2010-09-21 2017-12-20 アルター・バイオサイエンス・コーポレーション Multimeric IL-15 soluble fusion molecule and methods for its production and use
US9512401B2 (en) 2010-10-01 2016-12-06 Board Of Regents, The University Of Texas System B and T lymphocyte attenuator marker for use in adoptive T-cell therapy
HRP20181315T1 (en) 2010-11-22 2018-10-19 Amicus Therapeutics, Inc. NEW SIGNAL SEQUENCES TO IMPROVE PROTEIN EXPRESSION AND EXTRACTION OF RECOMBINANT ENZYMES AND OTHER PROTEINS
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2012083424A1 (en) 2010-12-21 2012-06-28 The University Of Western Ontario Novel amino acid linker sequences for ligand immobilization
WO2012092374A2 (en) 2010-12-31 2012-07-05 Short Jay M Express humanization of antibodies
EP2708561A4 (en) 2011-03-15 2014-09-24 Univ Yonsei Iacf BIO-NEEDLE
RU2632651C2 (en) 2011-05-11 2017-10-06 Чилдрен'С Медикал Сентер Корпорейшн Modified biotin-binding protein, fusion proteins based thereon and their application
PT3682905T (en) 2011-10-03 2022-04-07 Modernatx Inc Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
JP6053688B2 (en) 2011-10-07 2016-12-27 国立大学法人三重大学 Chimeric antigen receptor
JP6267644B2 (en) * 2011-10-20 2018-01-24 アメリカ合衆国 Anti-CD22 chimeric antigen receptor
ES2923757T3 (en) 2011-12-16 2022-09-30 Modernatx Inc Modified mRNA compositions
US20140359799A1 (en) 2011-12-23 2014-12-04 Case Western Reserve University Targeted gene modification using hybrid recombinant adeno-associated virus
WO2013091661A2 (en) 2011-12-23 2013-06-27 Aarhus Universitet Proteolytic resistant protein affinity tag
CN104411338A (en) 2012-04-02 2015-03-11 现代治疗公司 Modified polynucleotides for the production of biologics and proteins associated with human disease
MX360368B (en) 2012-04-27 2018-10-29 Bioatla Llc Modified antibody regions and uses thereof.
KR101520534B1 (en) 2012-05-07 2015-05-21 고려대학교 산학협력단 Method for enrichment and expansion of natural killer cells derived from peripheral blood mononuclear cells
EP3553089A1 (en) 2012-05-10 2019-10-16 Bioatla, LLC Multi-specific monoclonal antibodies
WO2013172926A1 (en) * 2012-05-14 2013-11-21 Yale University Immune biomarkers and assays predictive of clinical response to immunotherapy for cancer
DK3578201T3 (en) 2012-06-28 2023-05-08 Univ Of Central Florida Research Foundation Incorporated METHODS AND COMPOSITIONS FOR NATURAL KILLER CELLS
RU2015103816A (en) 2012-07-09 2016-08-27 Ф.Хоффманн-Ля Рош Аг CELLING PEPTIDES IN THE CELL, THE TARGET OF WHICH IS THE eIF4E
GB201212902D0 (en) 2012-07-20 2012-09-05 Univ Singapore Combinatoric encoding methods for microarrays
EP2899199B1 (en) 2012-09-19 2019-07-03 Gemvax & Kael Co., Ltd. Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate
WO2014053879A1 (en) 2012-10-04 2014-04-10 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
WO2014053880A1 (en) 2012-10-04 2014-04-10 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
WO2014056813A1 (en) 2012-10-08 2014-04-17 F. Hoffmann-La Roche Ag Cell penetrating peptides which bind irf5
US20150359853A1 (en) 2012-10-24 2015-12-17 Admune Therapeutics Llc Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes
US9444624B2 (en) 2012-11-02 2016-09-13 Facebook, Inc. Providing user authentication
EP3415525B1 (en) 2012-12-07 2022-01-05 Phion Therapeutics Limited An amphipathic peptide
AU2013204922B2 (en) 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
WO2014121005A1 (en) 2013-02-01 2014-08-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Retroviral vector packaging cell lines and methods of purifying and producing retroviral particles
IL305629A (en) * 2013-02-15 2023-11-01 Univ California Chimeric antigen receptor and methods of use thereof
US9675633B2 (en) * 2013-03-14 2017-06-13 Board Of Regents, The University Of Texas System miRNA for treating cancer and for use with adoptive immunotherapies
EP2997134B1 (en) * 2013-05-14 2020-06-24 Board of Regents, The University of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
JP6684215B2 (en) * 2013-08-28 2020-04-22 ピーシーアイ バイオテック エイエス Vaccination compound and immunization compound, and vaccination method and immunization method
WO2015039100A1 (en) 2013-09-16 2015-03-19 The Trustees Of The University Of Pennsylvania Cd137 enrichment for efficient tumor infiltrating lymphocyte selection
AU2014337367B2 (en) * 2013-10-15 2020-04-30 The Scripps Research Institute Peptidic chimeric antigen receptor T cell switches and uses thereof
GB201318347D0 (en) 2013-10-16 2013-11-27 Ucl Business Plc Retroviral vectors
ES2913205T3 (en) 2014-05-13 2022-06-01 Bioatla Inc Conditionally active biological proteins
PT3149025T (en) 2014-05-21 2019-08-01 Entrada Therapeutics Inc Cell penetrating peptides and methods of making and using thereof
BR112016027773B1 (en) 2014-05-29 2023-12-26 Procell Therapeutics Inc. BOTULINUM TOXIN CELL-PENETRATING RECOMBINANT PROTEIN, PHARMACEUTICAL COMPOSITION, COMPOSITION FOR AN EXTERNAL DERMAL AGENT AND COSMETIC COMPOSITION
US20160060313A1 (en) 2014-08-27 2016-03-03 Daewoong Jo Development of Protein-Based Biotherapeutics That Penetrates Cell-Membrane and Induces Anti-Angiogenic Effect - Improved Cell-Permeable Suppressor of Cytokine Signaling (iCP-SOCS3) Proteins, Polynucleotides Encoding the Same, and Anti-Angiogenic Compositions Comprising the Same
US10513699B2 (en) 2014-09-03 2019-12-24 Bioatla, Llc Discovering and producing conditionally active biologic proteins in the same eukaryotic cell production hosts
US20170239294A1 (en) 2014-10-15 2017-08-24 Novartis Ag Compositions and methods for treating b-lymphoid malignancies
WO2016113203A1 (en) * 2015-01-12 2016-07-21 Pieris Ag Engineered t cells and uses therefor
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
US11248058B2 (en) * 2015-02-19 2022-02-15 University Of Florida Research Foundation, Inc. Chimeric antigen receptors and uses thereof
US20180140602A1 (en) 2015-04-07 2018-05-24 Novartis Ag Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
CA3149413C (en) 2015-04-10 2025-07-08 Feldan Bio Inc. Polypeptide-based shuttle agents for improving the transduction efficiency of polypeptide cargos to the cytosol of target eukaryotic cells, uses thereof, methods and kits relating to same
WO2016168595A1 (en) 2015-04-17 2016-10-20 Barrett David Maxwell Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
WO2016210350A1 (en) 2015-06-25 2016-12-29 Amyris, Inc. Maltose dependent degrons, maltose-responsive promoters, stabilization constructs, and their use in production of non-catabolic compounds
US10550379B2 (en) 2015-06-29 2020-02-04 The Board Of Trustees Of The Leland Stanford Junior University Degron fusion constructs and methods for controlling protein production
US10829735B2 (en) 2015-07-21 2020-11-10 The Trustees Of The University Of Pennsylvania Methods for improving the efficacy and expansion of immune cells
EP3347375B1 (en) 2015-09-10 2020-12-23 The United States of America, as represented by The Secretary, Department of Health and Human Services Anti-cd276 chimeric antigen receptors
WO2017175072A1 (en) 2016-04-08 2017-10-12 Feldan Bio Inc. Peptide shuttle based gene disruption
WO2017180587A2 (en) 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Regulated biocircuit systems
KR20230100748A (en) * 2016-07-28 2023-07-05 노파르티스 아게 Combination therapies of chimeric antigen receptors adn pd-1 inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8173792B2 (en) * 2007-02-09 2012-05-08 The Board Of Trustees Of The Leland Stanford Junior University Method for regulating protein function in cells using synthetic small molecules
US20140010791A1 (en) * 2008-05-07 2014-01-09 The Board Of Trustees Of The Leland Stanford Junior University Methods for regulating protein function in cells in vivo using synthetic small molecules
WO2018231759A1 (en) * 2017-06-12 2018-12-20 Obsidian Therapeutics, Inc. Pde5 compositions and methods for immunotherapy

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ALEXANDRE JUILLERAT ET AL: "Design of chimeric antigen receptors with integrated controllable transient functions", SCIENTIFIC REPORTS, vol. 6, 11 January 2016 (2016-01-11), pages 18950, XP055271820, DOI: 10.1038/srep18950 *
MARI IWAMOTO ET AL: "A General Chemical Method to Regulate Protein Stability in the Mammalian Central Nervous System", CHEMISTRY & BIOLOGY, vol. 17, no. 9, 1 September 2010 (2010-09-01), GB, pages 981 - 988, XP055552908, ISSN: 1074-5521, DOI: 10.1016/j.chembiol.2010.07.009 *
See also references of WO2018161017A1 *

Also Published As

Publication number Publication date
WO2018161017A1 (en) 2018-09-07
SG10202001869VA (en) 2020-04-29
JP7341900B2 (en) 2023-09-11
AU2023214349C1 (en) 2026-07-23
CA3055202A1 (en) 2018-09-07
EP3589646A1 (en) 2020-01-08
CN110831961B (en) 2024-01-02
KR20200010181A (en) 2020-01-30
AU2023214349A1 (en) 2023-08-31
AU2018227583A1 (en) 2019-10-17
AU2018227583B2 (en) 2023-06-01
JP2025185029A (en) 2025-12-18
AU2023214349B2 (en) 2026-01-29
JP2023164900A (en) 2023-11-14
JP2020511529A (en) 2020-04-16
SG11201907922PA (en) 2019-09-27
CN110831961A (en) 2020-02-21
KR102746901B1 (en) 2024-12-26

Similar Documents

Publication Publication Date Title
MA49403A (en) PDE5 COMPOSITIONS AND IMMUNOTHERAPY METHODS
EP3679141C0 (en) METHODS AND COMPOSITIONS FOR INHIBITING LDHA EXPRESSION
EP3735685A4 (en) BILLBOARD
EP3445407A4 (en) COMPOSITIONS AND METHODS FOR CELLULAR IMMUNOTHERAPY
EP3532613A4 (en) METHODS AND COMPOSITIONS FOR RNA MAPPING
EP3750149C0 (en) BILLBOARD
EP3607587A4 (en) BILLBOARD
EP3906029A4 (en) MENIN-MLL INTERACTION INHIBITORS
MA44725A (en) LSD1 INHIBITOR FORMULATIONS
EP3353309A4 (en) COMPOSITIONS AND METHODS FOR GENOMIC EDITION
EP3446194A4 (en) APPLICATION SHORTCUTS FOR CARPLAY
EP3526328A4 (en) COMBINATION OF C3 INHIBITION
MA71468A (en) COMPOSITIONS AND METHODS FOR DECREASING TAU EXPRESSION
EP3798719A4 (en) BILLBOARD
EP3656821A4 (en) ASPHALT COMPOSITION
EP3635100A4 (en) COMPOSITIONS AND METHODS FOR EXPRESSING OTOFERLINE
CA185201S (en) EARRING
EP3302588A4 (en) COMPOSITIONS AND METHODS FOR ADHESION TO SURFACES
MA49006A (en) IP6K INHIBITORS
EP3752194A4 (en) ANTI-TUMOR IMMUNOTHERAPY COMPOSITIONS AND METHODS
EP3426349A4 (en) METHODS AND COMPOSITIONS FOR INHIBITING PMP22 EXPRESSION
EP4058062A4 (en) COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY
EP3820980A4 (en) ESTERQUATS COMPOSITIONS
EP3478315A4 (en) METHODS AND COMPOSITIONS FOR INHIBITING THE INHIBITOR IMMUNE RECEPTOR
EP3496882A4 (en) DAMPING PLATE

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20191001

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RIN1 Information on inventor provided before grant (corrected)

Inventor name: BRISKIN, MICHAEL JOSEPH

Inventor name: OLS, MICHELLE LYNN

Inventor name: DOLINSKI, BRIAN

Inventor name: SUN, DEXUE

Inventor name: EZELL, TUCKER

Inventor name: LI, DAN JUN

Inventor name: KOSMIDER, NICOLE

Inventor name: BALAKRISHNAN, VIJAYA

Inventor name: SURI, VIPIN

Inventor name: HELLER, SCOTT FRANCIS

Inventor name: KULKARNI, ABHISHEK

Inventor name: ELPEK, KUTLU GOKSU

RAV Requested validation state of the european patent: fee paid

Extension state: MD

Effective date: 20191001

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: C07K0014505000

Ipc: C12N0009060000

A4 Supplementary search report drawn up and despatched

Effective date: 20201218

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 14/55 20060101ALI20201214BHEP

Ipc: C07K 14/705 20060101ALI20201214BHEP

Ipc: C07K 16/30 20060101ALI20201214BHEP

Ipc: A61K 31/505 20060101ALI20201214BHEP

Ipc: C12N 9/64 20060101ALI20201214BHEP

Ipc: A61K 35/00 20060101ALI20201214BHEP

Ipc: A61K 31/519 20060101ALI20201214BHEP

Ipc: C12N 9/02 20060101ALI20201214BHEP

Ipc: C07K 14/54 20060101ALI20201214BHEP

Ipc: A61P 37/02 20060101ALI20201214BHEP

Ipc: A61K 38/00 20060101ALI20201214BHEP

Ipc: C07K 14/725 20060101ALI20201214BHEP

Ipc: C12N 15/62 20060101ALI20201214BHEP

Ipc: A61P 35/00 20060101ALI20201214BHEP

Ipc: A61K 39/00 20060101ALI20201214BHEP

Ipc: C07K 16/28 20060101ALI20201214BHEP

Ipc: A61K 39/39 20060101ALI20201214BHEP

Ipc: A61K 35/14 20150101ALI20201214BHEP

Ipc: C12N 9/06 20060101AFI20201214BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20241202